Biotech Enterprise Investments

(for the Scientist, Physician, Biomedical Entrepreneur, Investment & Financial Executive, Graduate) 

(January 14, 2026 to March 25, 2026)

‍Biotech Enterprise Investments: From Concept to Capital
Live Online + Asynchronous | 10 Weeks* | Tuition: $2,495
Wednesday, January 14 – Wednesday, March 25, 2026

About the Course

Biotech is one of the world’s most dynamic and capital-intensive sectors. Success requires more than scientific insight; it demands the ability to translate discovery into viable commercial and investment opportunities.

This course bridges science, strategy, finance, and ethics to equip participants with the skills needed to develop, evaluate, and position biotechnology ventures. Through SEGP’s BLO team framework, participants work collaboratively to produce real, investment-ready concepts addressing unmet clinical, environmental, or industrial needs.

What You’ll Learn
• Evaluate biotech business models and venture pathways
• Convert complex research into investor-ready cases
• Navigate regulatory, IP, and market-entry considerations
• Build financial projections and capital strategies
• Integrate bioethical principles into product development
• Present venture concepts to a simulated or live investor panel

Team-Based Venture Development
Participants form interdisciplinary teams to develop new biotech product concepts, assess feasibility and commercial potential, build a pitch deck, and present their ventures for either feedback or could result in direct investment.

Who Should Enroll
Entrepreneurs, investors, scientists, clinicians, life-science professionals, and graduate-level students seeking hands-on experience in biotech commercialization and venture creation.

Instructor
Daniel (E. St. Mark) Latty, PhD is an investor, operator, and educator with more than 25 years bridging life sciences, finance, and real assets. He has led and taught biotechnology business programs at a research university, developed venture teams across therapeutic, diagnostic, environmental, agricultural, and industrial domains, and previously designed and taught the Venture Capital & Private Equity MBA course at Howard University. He holds advanced degrees in biotechnology, finance, data science, and real estate development, and previously pursued a medical doctoral degree program. He has attended Carnegie Mellon, Harvard, Johns Hopkins, NYU, and the University of Pittsburgh.

Enrollment is limited. Registration Below.

Course Format

‍The course is virtual and includes investor pitch opportunities, bioethical analysis, and team-based venture / product creation. ‍

‍The course is both live and asynchronous for projects and recorded lectures.

Online sessions are on Wednesdays 6:30 PM EST to 9:00 PM EST. Sessions are recorded if missed, but live interaction is encouraged.

‍Course will be offered on a platform and uses certain tools allowing participants to work seamlessly in different time zones and locations.

‍Course participants gain access to instructor and experts outside of live class time.

The course structure, enrichment activities, and team dynamics may lead team members to develop vibrant network of life-long friends and business associates.

During or at the end of the course, it is a possibility that participants may analyze, launch, or grow new or existing biotech enterprises or develop new product-concepts. A followup Strategic Biotechnology Development & Investments course is being planned as a sequel to this course.

• *Note: An optional one week free prerequisite session is available for registered participants who need preliminary workup depending if you are from a science/technical or investments background. This may result in 11 weeks if you join the registered free session that would take place between January 7, 2026 and January 14, 2026 between 7:00 PM EST and 9:00 PM EST. Regular course sessions will be recorded but preliminary sessions may not be recorded.